影像组学在预测局部晚期乳腺癌患者早期疾病复发中的作用:影像组学特征与RECIST标准的整合
本研究回顾性分析238例接受新辅助治疗(NAT)的乳腺癌患者,利用治疗前乳腺MRI提取影像组学特征,并结合临床与影像学变量构建预测早期疾病复发(EDR)的模型。整合治疗前MRI影像组学与治疗后RECIST缓解数据的放射-影像组学模型预测EDR性能最高(AUC 0.77,敏感度0.85)。结论认为该联合方法可增强EDR预测,支持精准医学,但需更大队列进一步验证。
要点
- 治疗前MRI影像组学联合治疗后RECIST缓解评估的模型对EDR预测性能最高(AUC 0.77,敏感度0.85)。
- 内部验证证实该放射-影像组学模型具有稳健性。
- 作者认为联合影像组学与RECIST评估有助于乳腺癌精准治疗策略与随访计划。
核心结论
- 将治疗前MRI影像组学特征与治疗后MRI的RECIST缓解评估相结合,可增强对乳腺癌患者早期疾病复发的预测。
研究设计与样本
- 回顾性分析238例接受新辅助治疗的乳腺癌患者,使用治疗前和治疗后乳腺MRI进行评估。
- 提取影像组学特征并与临床及影像学数据结合,构建预测早期疾病复发的模型。
- 采用AUC、准确率、敏感度和特异度指标评估模型。
关键影像表现/征象
- 放射-影像组学模型整合了治疗前MRI影像组学与RECIST缓解数据,对EDR的预测性能最高(AUC 0.77,敏感度0.85)。
诊断标准与关键数值
- 放射-影像组学模型预测EDR的AUC为0.77,敏感度为0.85。
- 原文未报告该模型的特异度和准确率数值。
临床应用与阅片要点
- 作者认为,联合治疗前MRI影像组学与治疗后RECIST缓解评估可支持乳腺癌精准治疗策略及随访规划。
局限性
- 原文结论指出,需在更大队列中进一步验证以确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Breast cancer (BC) is a major global health issue with significant heterogeneity among its subtypes. Neoadjuvant treatment (NAT) has been extended to include early BC patients, particularly those with HER2 + and triple-negative subtypes, to achieve pathological complete response and improve long-term outcomes. However, disease recurrence remains a challenge, highlighting the need for predictive biomarkers. This study evaluates the role of radiomics from pre-treatment breast MRI, integrated with clinical and radiological variables, in predicting early disease recurrence (EDR) after NAT.
METHODS: A retrospective analysis was conducted on 238 BC patients treated with NAT and assessed using pre- and post-treatment breast MRI. Radiomic features were extracted and combined with clinical and radiological data to develop predictive models for EDR. Models were evaluated using AUC, accuracy, sensitivity, and specificity metrics.
RESULTS: The radiological-radiomic model, which integrated pre-treatment MRI radiomics with RECIST response data, demonstrated the highest predictive performance for EDR (AUC 0.77, sensitivity 0.85). Internal validation confirmed the robustness of the model.
CONCLUSION: Combining radiomic features from pre-NAT MRI with RECIST response evaluation from post-NAT MRI enhances the prediction of EDR in BC patients, supporting precision medicine in treatment strategies and follow-up planning. Further validation on larger cohorts is needed to confirm these findings.
引用
- Trombadori C, Boccia E, Tran EH, et al. Role of radiomics in predicting early disease recurrence in locally advanced breast cancer patients: integration of radiomic features and RECIST criteria. Radiol Med. 2025. PMID: 40117102. doi:10.1007/s11547-025-01984-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。